Hims reports $33 million loss after shifting focus to GLP-1 market
read at STAT ↗EarningsNegative
Hims said its latest earnings were hit by a $33 million charge tied to a strategic shift toward GLP-1 treatments.
The charge stems from costs of redirecting product development and marketing resources as the company pursues the fast-growing GLP-1 market.
Analysts view the loss as a reminder of the financial risks digital-health firms face when entering highly competitive therapeutic areas.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’”
read at STAT ↗484 words · retrieved May 12
comments(0)
5-min edit window · permanent after that